axa1125

Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study Lucy E.M. Finnigan Mark Philip Cassar Margaret James Koziel Joel Pradines Hanan Lamlum Karim Azer et al...

Oxford to test potential treatment for fatigue in long COVID patients https://www.ox.ac.uk/news/2021-10-29-oxford-test-potential-treatment-fatigue-long-covid-patients Dr Alison Schecter, President of R&D at Axcella, said: 'While Long COVID’s enormous patient and socioeconomic burden has become...